These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 30238838)

  • 21. Extemporaneous Compounding of Oral Acitretin Suspension for Pediatric Patient with Generalized Pustular Psoriasis.
    Choo W
    Int J Pharm Compd; 2016; 20(1):6-10. PubMed ID: 27125051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmaceutical compounding of orphan active ingredients in Belgium: how community and hospital pharmacists can address the needs of patients with rare diseases.
    Vanhoorne V; Peeters E; Van Tongelen I; Boussery K; Wynendaele E; De Spiegeleer B; Remon JP; Vervaet C
    Orphanet J Rare Dis; 2019 Aug; 14(1):186. PubMed ID: 31370862
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Access to age-appropriate essential medicines: a retrospective survey of compounding of medicines for children in hospitals in Nigeria and implications for policy development.
    Orubu ES; Okwelogu C; Opanuga O; Nunn T; Tuleu C
    Health Policy Plan; 2017 Mar; 32(2):225-235. PubMed ID: 28207051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extemporaneous compounding activities and the associated informational needs of pharmacists.
    Crawford SY; Dombrowski SR
    Am J Hosp Pharm; 1991 Jun; 48(6):1205-10. PubMed ID: 1858798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stability of three commonly compounded extemporaneous enrofloxacin suspensions for oral administration to exotic animals.
    Petritz OA; Guzman DS; Wiebe VJ; Papich MG
    J Am Vet Med Assoc; 2013 Jul; 243(1):85-90. PubMed ID: 23786194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physicochemical and microbiological stability studies of extemporaneous antihypertensive pediatric suspensions for hospital use.
    Mendes C; Costa AP; Oliveira PR; Tagliari MP; Silva MA
    Pharm Dev Technol; 2013; 18(4):813-20. PubMed ID: 22670721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liquid dosage forms extemporaneously prepared from commercially available products - considering new evidence on stability.
    Haywood A; Glass BD
    J Pharm Pharm Sci; 2013; 16(3):441-55. PubMed ID: 24021292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of Extemporaneous Prescriptions Prescribed by Dermatovenerologists in Latvia and Comparison with Standardized Compounded Preparation Monographs of Germany and USA.
    Kiseļova O; Mauriņa B; Šidlovska V
    Medicina (Kaunas); 2020 Jan; 56(1):. PubMed ID: 31936697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quality evaluation of extemporaneous delayed-release liquid formulations of lansoprazole.
    Melkoumov A; Soukrati A; Elkin I; Forest JM; Hildgen P; Leclair G
    Am J Health Syst Pharm; 2011 Nov; 68(21):2069-74. PubMed ID: 22011986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extemporaneous drug formulations.
    Nahata MC; Allen LV
    Clin Ther; 2008 Nov; 30(11):2112-9. PubMed ID: 19108799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preparation and stability of extemporaneous oral liquid formulations of oseltamivir using commercially available capsules.
    Winiarski AP; Infeld MH; Tscherne R; Bachynsky M; Rucki R; Nagano-Mate K
    J Am Pharm Assoc (2003); 2007; 47(6):747-55. PubMed ID: 18032138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extemporaneous Compounding and Physiological Modeling of Amlodipine/Valsartan Suspension.
    Aabed WJ; Radwan AH; Zaid AN; Shraim NY
    Int J Hypertens; 2021; 2021():6695744. PubMed ID: 33824764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stability of extemporaneous enalapril maleate suspensions for pediatric use prepared from commercially available tablets.
    Sosnowska K; Winnicka K; Czajkowska-Kośnik A
    Acta Pol Pharm; 2009; 66(3):321-6. PubMed ID: 19645333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extemporaneous (magistral) preparation of oral medicines for children in European hospitals.
    Brion F; Nunn AJ; Rieutord A
    Acta Paediatr; 2003 Apr; 92(4):486-90. PubMed ID: 12801118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the Stability of Mercaptopurine Suspension Compounded in a Commercial Vehicle and the Determination of an Appropriate Beyond-use Date.
    Peacock GF; Sauvageot J; Hill A; Killian A
    Int J Pharm Compd; 2016; 20(1):81-5. PubMed ID: 27125058
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of Rheological and Sedimentation Behavior of Commercially Available Suspending Vehicles for Oral Pharmaceutical Preparations.
    Visser JC; Ten Seldam IEJ; van der Linden IJ; Hinrichs WLJ; Veenendaal RFH; Dijkers ECF; Woerdenbag HJ
    Int J Pharm Compd; 2018; 22(3):247-251. PubMed ID: 29878892
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lipophilic Ready-to-use Vehicles and Compounded Topical Medications.
    Lacassia C; Spennacchio A; Lopalco A; Lopedota AA; la Forgia FM; Fontana S; Franco M; Denora N
    Int J Pharm Compd; 2024; 28(2):146-150. PubMed ID: 38604141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hydrophilic Ready-to-use Vehicles and Compounded Topical Medications.
    Spennacchio A; Lacassia C; Lopalco A; Lopedota AA; la Forgia FM; Fontana S; Franco M; Denora N
    Int J Pharm Compd; 2024; 28(2):138-145. PubMed ID: 38604140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Basics of Compounding: Compounding Films.
    Allen LV
    Int J Pharm Compd; 2016; 20(4):298-305. PubMed ID: 28333675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary packaging considerations in developing medicines for children: oral liquid and powder for constitution.
    Campbell GA; Vallejo E
    J Pharm Sci; 2015 Jan; 104(1):52-62. PubMed ID: 25393927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.